Cost-effectiveness analysis of nivolumab-chemotherapy as first-line therapy for locally advanced/metastatic gastric cancer: a United States payer perspective.

Srujitha Marupuru,Daniel Arku,David R Axon,Lorenzo Villa-Zapata,Mohsen Yaghoubi,Marion K Slack,Terri Warholak

Expert review of pharmacoeconomics & outcomes research（2023）

引用 0|浏览7

暂无评分

摘要

From the US payer perspective, at a willingness to pay threshold of $US150,000/QALY, nivolumab-chemotherapy was not found to be cost-effective as a first line therapy for locally advanced/metastatic gastric cancer.

查看译文

关键词

gastric cancer, nivolumab, cost-effectiveness, trial, metastatic

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要